Volume 2, Issue 4, November 2017, Page: 106-114
Statins Effects on Diabetic Retinopathy Among Patients with Type 2 Diabetes Mellitus
Mohamed Anwar Hammad, Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia
Dzul Azri Mohamed Noor, Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia
Syed Azhar Syed Sulaiman, Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia
Tarek Mohamed Elsayed, Department of Pharmacy Practice, Kulliyyah of Pharmacy, International Islamic University Malaysia, Kuantan, Malaysia
Received: Jul. 30, 2017;       Accepted: Aug. 21, 2017;       Published: Sep. 21, 2017
DOI: 10.11648/j.ijovs.20170204.15      View  1449      Downloads  103
Abstract
Diabetic Retinopathy (DR) is the leading cause of vision loss in adults aged 20–74 years. DR classified as the fifth most common cause of preventable blindness and fifth furthermost common cause of moderate to severe visual impairment. A retrospective cohort study was performed to evaluate the prevalence of DR, and the effect of statins on the DR, among outpatients with Type 2 diabetes mellitus. The study was done at the endocrine clinic in Hospital Pulau Pinang, Malaysia. Two cohorts of 717 diabetic outpatients (559 statins user and 158 statins non-users) were investigated for demographic data and diagnosis of DR. Findings were presented as descriptive statistics. The age of 717 subjects was (55.2±14.9) years and females 367 (51.2%). About 166 (23.2%) patients had DR with age (58.2±14.9) years. From 559 (78%) outpatients were statins-user, 143 (25.6%) had DR with age (58.5±14.9) years. While the control group 158 (22%) participants, only 23 (14.6%) had DR with age (56.3±14.9) years. The relative risk (RR) for DR in the statin-user group for DR is 1.75 and excessive relative risk (ERR) 75%. The absolute risk (AR) is 11% and number need to harm (NNH) is 9. Nearly one-quarter of the subjects had diabetic retinopathy. The risk of diabetic retinopathy incidence is higher in the statins user group than statins non-user cohort.
Keywords
Eye, Malaysia, Diabetic Retinopathy, Statins, Type 2 Diabetes Mellitus
To cite this article
Mohamed Anwar Hammad, Dzul Azri Mohamed Noor, Syed Azhar Syed Sulaiman, Tarek Mohamed Elsayed, Statins Effects on Diabetic Retinopathy Among Patients with Type 2 Diabetes Mellitus, International Journal of Ophthalmology & Visual Science. Vol. 2, No. 4, 2017, pp. 106-114. doi: 10.11648/j.ijovs.20170204.15
Copyright
Copyright © 2017 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
F. Bandello, R. Lattanzio, I. Zucchiatti and C. Del Turco, “Pathophysiology and treatment of diabetic retinopathy,” Acta. Diabetol., vol. 50, issue 1, 2013. doi: 10.1007/s00592-012-0449-3.
[2]
L. Wu, P. Fernandez-Loaiza, J. Sauma, E. Hernandez-Bogantes and M. Masis, “Classification of diabetic retinopathy and diabetic macular edema,” World J. Diabetes, vol. 4, pp. 290–294, 2013. doi: 10.4239/wjd.v4.i6.290.
[3]
R. Madonna, G. Giovannelli, P. Confalone, F. V. Renna, Y. J. Geng and R. De Caterina, “High glucose-induced hyperosmolarity contributes to COX-2 expression and angiogenesis: implications for diabetic retinopathy,” Cardiovasc. Diabetol., vol. 15, issue 18, 2016. doi: 10.1186/s12933-016-0342-4.
[4]
M. A. Hammad, A. A. Khamis, K. M. Al- Akhali, T. M. Elsayed, A. M. Alasmri, E. M. Al-Ahmari, et al. “Evaluation of Drug Dosing in Renal Failure,” IOSR-JPBS, vol. 11, issue 5, suppl, 3, pp. 39-50, 2016. DOI: 10.9790/3008-1105033950.
[5]
R. Benarous, M. B. Sasongko, S. Qureshi, E. Fenwick, M. Dirani, T. Y. Wong and E. L. Lamoureux, “Differential association of serum lipids with diabetic retinopathy and diabetic macular edema,” Invest. Ophthalmol. Vis. Sci., vol. 52, pp. 7464–7469, 2011. doi: 10.1167/iovs.11-7598.
[6]
R. Crosby-Nwaobi, I. Chatziralli, T. Sergentanis, T. Dew, A. Forbes and S. Sivaprasad, “Cross talk between lipid metabolism and inflammatory markers in patients with diabetic retinopathy,” J. Diabetes Res., vol. 2015, issue 191382, 2015. doi: 10.1155/2015/191382.
[7]
Y. R. Chung, S. W. Park, S. Y. Choi, S. W. Kim, K. Y. Moon, J. H. Kim and K. Lee, “Association of statin use and hypertriglyceridemia with diabetic macular edema in patients with Type 2 diabetes and diabetic retinopathy,” Cardiovasc. Diabetol., vol. 16, issue 4, 2017. http://doi.org/10.1186/s12933-016-0486-2.
[8]
N. Cheung, P. Mitchell and T. Y. Wong, “Diabetic retinopathy,” Lancet. Vol. 376, issue 9735, pp. 124-36, 2010. doi: 10.1016/S0140-6736(09)62124-3.
[9]
R. R. Bourne, G. A. Stevens, R. A. White, J. L. Smith, S. R. Flaxman, H. Price, et al., “Causes of vision loss worldwide, 1990–2010: a systematic analysis,” Lancet Glob Health, vol. 1, issue 6, pp. e339–49, 2013. doi: 10.1016/S2214-109X(13)70113-X.
[10]
J. W. Yau, S. L. Rogers, R. Kawasaki, E. L. Lamoureux, J. W. Kowalski, T. Bek, et al., “Global prevalence and major risk factors of diabetic retinopathy,” Diabetes Care, vol. 35, issue 3, pp. 556–64, 2012. doi: 10.2337/dc11-1909.
[11]
R. Lee, T. Y. Wong, and C. Sabanayagam, “Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss,” Eye and Vision, vol. 2, issue 17, 2015. doi:10.1186/s40662-015-0026-2.
[12]
P. Chous, “New strategies to assess the risk of diabetes-related vision loss,” Diabetes. Optometry Times, vol. 9, issue 6, pp. 20-27, Jun 2017.
[13]
M. A. Hammad, D. A. Mohamed Noor, S. A. Sulaiman, M. A. Al-Mansoub and M. Qamar, “A Retrospective Study on the Age of Onset for Type 2 Diabetes Diagnosis,” World Academy of Science, Engineering and Technology, International Science Index, Pharmacological and Pharmaceutical Sciences, vol. 4, issue 8, p. 982, 2017. DOI: 10.13140/RG.2.2.24224.69124. https://www.accp.com/docs/meetings/abstracts/2013_virtual.pdf.
[14]
M. A. Hammad, B. Tangiisuran, N. Abd El Aziz and Y. Hassan, “A prospective study of uncontrolled glycaemia secondary to drug-drug interactions in Type 2 diabetes mellitus patients at Penang general hospital in Malaysia” Pharmacotherapy, vol. 33, issue 5, pp. E50-E50, 2013. DOI: 10.13140/RG.2.1.2049.1281, https://www.accp.com/docs/meetings/abstracts/2013_virtual.pdf.
[15]
M. A. Hammad, D. A. Mohamed Noor, S. A. Syed Sulaiman, N. A. Aziz and Y. Elsobky, “A prospective study of prevalence of uncontrolled glycaemia in Type 2 diabetes mellitus outpatients” Pharmacotherapy, vol. 36, pp. e83–e138, 2016. DOI: 10.13140/RG.2.1.4848.0247/1. https://www.accp.com/docs/meetings/abstracts/2016_virtual.pdf.
[16]
J. G. Robinson, “Statins and diabetes risk: how real is it and what are the mechanisms?” Curr. Opin. Lipidol., vol. 26, pp. 228–235, 2015. doi: 10.1097/MOL.0000000000000172.
[17]
S. Simsek, C. G. Schalkwijk and B. H. Wolffenbuttel, “Effects of rosuvastatin and atorvastatin on glycaemic control in Type 2 diabetes—the CORALL study,” Diabet. Med., Vol. 29, pp. 628–631, 2012. doi: 10.1111/j.1464-5491.2011.03553.x.
[18]
R. V. Shah and A. B. Goldfine, “Statins and risk of new-onset diabetes mellitus, ”Circulation., Vol. 126, pp. e282–e284, 2012. doi: 10.1161/CIRCULATIONAHA.112.122135.
[19]
H. Cederberg, A. Stancakova, N. Yaluri, S. Modi, J. Kuusisto and M. Laakso, “Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6-year follow-up study of the METSIM cohort” Diabetologia, vol. 58, pp. 1109–1117, 2015. doi: 10.1007/s00125-015-3528-5.
[20]
M. H. Hammad, D. A. Mohamed Noor, S. A. Syed Sulaiman, A. A. Khamis, A. Kharshid and N. A. Aziz, “Comparison of Statins Dose Intensity on HbA1c Control in Outpatients with Type 2 Diabetes: A Prospective Cohort Study,” World Academy of Science, Engineering and Technology, International Science Index 128, International Journal of Medical, Health, Biomedical, Bioengineering and Pharmaceutical Engineering, vol. 11, issue 8, pp. 423–428, 2017.
[21]
M. A. Hammad, D. A. Mohamed Noor, S. A. Syed Sulaiman, A. Kharshid, N. A. Aziz and T. M. Elsayed, “A Prospective Study on the Evaluation of Statins Usage on HbA1c Control among Type 2 Diabetes Mellitus in an Outpatients Setting” World Academy of Science, Engineering and Technology, International Science Index, Pharmacological and Pharmaceutical Sciences, vol. 4, issue 8, p. 978, 2017. DOI: 10.13140/RG.2.2.27914.36806
[22]
S. F. Nielsen and B. G. Nordestgaard, “Statin use before diabetes diagnosis and risk of microvascular disease: a nationwide nested matched study” Lancet Diabetes Endocrinol., vol. 2, pp. 894–900, 2014. doi: 10.1016/S2213-8587(14)70173-1. file:///C:/Users/USER/Downloads/Comparison%20of%20Statins%20Dose%20Intensity%20on%20HbA1c%20-%20Paper%20(1).pdf
[23]
Mansi, C. R. Frei, C. P. Wang and E. M. Mortensen, “Statins and new-onset diabetes mellitus and diabetic complications: a retrospective cohort study of US healthy adults,” J. Gen. Intern. Med., vol. 30, pp. 1599–1610, 2015. doi: 10.1007/s11606-015-3335-1.
[24]
N. J. Stone, J. G. Robinson, A. H. Lichtenstein, C. N. Bairey Merz, C. B. Blum, R. H. Eckel, A. C. Goldberg, D. Gordon, D. Levy, D. M. Lloyd-Jones, et al., “2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,” Circulation, vol. 129, pp. S1–S45, 2014. doi: 10.1161/01.cir.0000437738.63853.7a.
[25]
National Medical Research Register, National Institute of Health NIH guideline. (updated 11-Jun-2017) Available at: https://www.nmrr.gov.my/fwbLoginPage.jsp?fwbPageId=NMRR_Home (Accessed: 7- Jun -2017).
[26]
I. P. Chatziralli, “The Role of Dyslipidemia Control in the Progression of Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus,” Diabetes Ther., vol. 8, issue 2, pp. 209-212, 2017.
[27]
E. Ioannidou, V. S. Tseriotis and K. Tziomalos, “Role of lipid-lowering agents in the management of diabetic retinopathy,” World J. Diabetes, vol. 8, issue 1, pp. 1-6, 2017.
[28]
V. Mizranita and E. H. Pratisto, “Statin-associated ocular disorders: the FDA and ADRAC data,” Int J Clin Pharm., vol. 37, issue 5, pp. 844-50, 2015.
[29]
A. P. Khawaja, M. P. Chan, D. C. Broadway, D. F. Garway-Heath, R. Luben, J. L. Yip, S. Hayat, et al., “Systemic medication and intraocular pressure in a British population: the EPIC-Norfolk Eye Study,” Ophthalmology, vol 121, issue 8, pp. 1501-7, Aug 2014.
[30]
F. W. Fraunfelder and A. B. Richards, “Diplopia, blepharoptosis, and ophthalmoplegia and 3- hydroxy-3-methyl-glutaryl-CoA reductase inhibitor use,” Ophthalmology, vol. 115, issue 12, pp. 2282-2285, 2008.
[31]
F. W. Fraunfelder, “Ocular hemorrhage possibly the result of HMG-CoA reductase inhibitors,” J. Ocul. Pharmacol. Ther., vol. 20, issue 2, pp. 179-82, 2004.
[32]
M. Asghar, M. Rehman, M. Z. Khan, M. Abdur Rehman and M. Z. Tahir, “Frequency of Retinopathy and its Different Grades among Type II Diabetic Patients with Metabolic Syndrome in our population,” Pak. J. Ophthalmol., vol. 30, issue 4, pp. 219-223, 2014.
[33]
C. K. Kramer, T. C. Rodrigues, L. H. Canani, J. L. Gross and M. J. Azevedo, “Diabetic Retinopathy Predicts All-Cause Mortality and Cardiovascular Events in Both Type 1 and 2 Diabetes: Meta-analysis of observational studies. Diabetes Care,” vol. 34, issue 5, pp. 1238–44, 2011. doi:10.2337/dc11-0079
[34]
J. Nasser, F. Habib, B. Al Tajer, M. Al Tajer, F. Juma and M. Almohri, “Risk Factors for Diabetic Retinopathy in Patients Attending Primary Care Settings. Bahrain Medical Bulletin,” vol. 36, issue 1, pp. 1-9, 2014.
[35]
E. Y. Chew, W. T. Ambrosius and M. D. Davis, “Effects of Medical Therapies on Retinopathy Progression in Type2 Diabetes,” N Engl. J. Med., vol. 363, issue 3, pp. 233-44, 2010.
[36]
Q. Mohamed, M. C. Gillies and T. Y. Wong, “Management of Diabetic Retinopathy. A Systematic Review,” JAMA, vol, 298, issue 8, PP. 902-16, 2007.
[37]
J. Zhang and G. McGwin, “Association of Statin Use with the Risk of Developing Diabetic Retinopathy” Arch. Ophthalmol., vol. 125, issue 8, PP. 1096-1099, 2007.
[38]
M. Stratton, E. M. Kohner, S. J. Aldington, R. C. Turner, R. R. Holman, S. E. Manley, et al. “UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis,” Diabetologia, vol. 44, pp. 156–63, 2001.
[39]
C. S. H. Tan, E. M. Q. Gay and W. K. Ngo, “Is age a risk factor for diabetic retinopathy?” Br J Ophthalmol., vol. 94, issue 9, p. 1268, 2010.
[40]
R. Klein, B. E. Klein, S. E. Moss, M. D. Davis and D. L. DeMets, “The Wisconsin Epidemiologic Study of diabetic retinopathy III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years,” Arch. Ophthalmol., vol. 102, issue 4, pp. 527–32, 1984. doi:10.1001/archopht.1984.01040030405011.
[41]
R. Klein, E. K. Klein, S. E. Moss and K. J. Cruickshanks, “The Wisconsin Epidemiologic Study of diabetic retinopathy XIV. Ten-year incidence and progression of diabetic retinopathy,” Arch. Ophthalmol., vol. 112, issue 9, pp. 1217–28, 1994. doi:10.1001/archopht.1994.01090210105023.
[42]
K. Hietala, V. Harjutsalo, C. Forsblom, P. Summanen and P-H. Groop on behalf of the FinnDiane Study Group, “Age at Onset and the Risk of Proliferative Retinopathy in Type 1 Diabetes” Diabetes Care, vol. 33, issue 6, pp. 1315-1319, 2010. doi:10.2337/dc09-2278.
[43]
L. L. Lim, S. Y. Lee, C. L. Cheng, D. W. Wong, S. G. Ong, C. L. Ang, et al., “Diabetic retinopathy in diabetics referred to a tertiary centre from a nationwide screening programme,” Ann. Acad. Med. Singapore., vol. 37, pp. 753-9, 2008. PMID: 18989491.
[44]
R. Raman, K. Vaitheeswaran, K. Vinita and T. Sharma, “Is Prevalence of Retinopathy Related to the Age of Onset of Diabetes? Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetic Report No. 5” Ophthalmic. Res., vol. 45, pp. 36–41, 2011. DOI: 10.1159/000314720.
[45]
S. Y. Wang, C. A. Andrews, W. H. Herman, T. W. Gardner and J. D. Stein, “Incidence and Risk Factors for Developing Diabetic Retinopathy among Youths with Type 1 or Type 2 Diabetes throughout the United States,” Ophthalmology, vol. 124, issue 4, pp. 424-430, April 2017.
[46]
Y. R. Chung, S. W. Park, S. Y. Choi, S. W. Kim, K. Y. Moon, J. H. Kim and K. Lee, “Association of statin use and hypertriglyceridemia with diabetic macular edema in patients with type 2 diabetes and diabetic retinopathy,” Cardiovasc. Diabetol., vol. 16, issue 1, suppl. 4, 2017.
[47]
R. Williams, M. Airey, H. Baxter, J. Forrester, T. Kennedy-Martin and A. Girach, “Epidemiology of diabetic retinopathy and macular oedema: a systematic review” Eye, vol. 18, pp. 963–983, 2004. Doi:10.1038/sj.eye.6701476.
[48]
A. Davis, A Baldwin, M. Hingorani, A. Dwyer and D. Flanagan, “A review of 145 234 ophthalmic patient episodes lost to follow-up,” Eye, vol. 31, pp. 422–429, 2017. Doi:10.1038/eye.2016.225.
[49]
S. F. Nielsen and B. G. Nordestgaard. Statin use before diabetes diagnosis and risk of microvascular disease: a nationwide nested matched study. Lancet Diabetes Endocrinol., vol. 2, issue 11, pp. 894-900, 2014.
[50]
S. Fujii, C. Setoguchi, K. Kawazu and K. Hosoya, “Functional Characterization of Carrier-Mediated Transport of Pravastatin across the Blood-Retinal Barrier in Rats, “Drug Metab. Dispos., vol. 43, issue 12, pp. 1956-1959, 2015.
Browse journals by subject